PARP Inhibitor for Metastatic Breast Cancer

Specific PHGKB|Cancer|PHGKB

Breast Cancer Genomics

- Cancer PHGKB -

What's New

Last Posted: Jun 16, 2017

---

• PARP Inhibitor for Metastatic Breast Cancer  
  NEJM Journal Watch, June 14, 20
• [Making better use of the clinical geneticist's expertise; treating physician could request a DNA test for most cancer patients].  
  Aalfs C M et al. Nederlands tijdschrift voor geneeskunde 2017 161(0) D1525
• Assessing Breast Cancer Risk Estimates Based on the Gail Model and Its Predictors in Qatari Women.  
  Bener Abdulbari et al. Journal of primary care & community health 2017 Jul 8(3) 180-187
• Clinical outcomes of female breast cancer according to BRCA mutation status.  
  Cronin-Fenton Deirdre P et al. Cancer epidemiology 2017 Jun 49128-137
• Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer.  
  Nolan Emma et al. Science translational medicine 2017 Jun 9(393)
• Disparities in compliance with the Oncotype DX breast cancer test in the United States: A National Cancer Data Base assessment.  
  Kozick Zachary et al. American journal of surgery 2017 Jun
• Evaluating the NCCN Clinical Criteria for Recommending BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.  
  Cropper Caiqian et al. Journal of the National Comprehensive Cancer Network : JNCCN 2017 Jun 15(6) 797-803
• Genomic Study Seeks Clues to Help Explain Breast Cancer Disparities  
  NCI, June 13, 2017
• Performance of BRCA1/2 mutation prediction models in male breast cancer patients.  
  Moghadasi Setareh et al. Clinical genetics 2017 Jun
• Pharmacogenetics in cancer therapy - 8 years of experience at the Institute for Oncology and Radiology of Serbia.  
  Cavic Milena et al. Journal of B.U.ON. : official journal of the Balkan Union of Oncology 21(5) 1287-1295